<DOC>
	<DOCNO>NCT00162669</DOCNO>
	<brief_summary>Primary liver cancer ( hepatocellular carcinoma ) fifth common malignant disorder , increase incidence Europe USA result high prevalence hepatitis C. Most patient suitable potentially curative treatment . There standard palliative treatment patient advance hepatocellular carcinoma ( HCC ) , drug demonstrate efficient disease term survival . The use anti-vascular agent might promise approach view highly vascular nature tumor . The aim phase II trial evaluate potential benefit bevacizumab term disease control rate , progression-free overall survival adult patient advance primary liver cancer . Bevacizumab angiogenesis inhibitor already successfully used patient colorectal renal cancer .</brief_summary>
	<brief_title>Bevacizumab Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Histologically cytologically proven HCC alphafetoprotein level &gt; 400 ng/ml together hypervascular tumor cirrhosis document CT scan MRI . HCC amenable curative treatment ( resection , transplantation , percutaneous ablation ) Presence least one dimensionally measurable target lesion large diameter &gt; = 2 cm . No previous chemoembolization , previous radiotherapy Cancer Liver Italian Program ( CLIP ) score &lt; 4 World Health Organization ( WHO ) performance status 2 less Life expectancy &gt; = 3 month . Age &gt; = 18 year . Adequate hematologic function ( neutrophil count , least 1500 per cubic millimeter ; platelet count , least 75,000 per cubic millimetre ; Hemoglobin , least 8 g/dl ) Adequate liver function ( bilirubin , 2 time upper limit normal ) ; Adequate renal function ( serum creatinine , less 150 micromol per liter ) Adequate coagulation function Written inform consent Decompensated cirrhosis ( ChildPugh score &gt; 7 ) CLIP score &gt; 4 Variceal bleed previous 3 month Thromboembolic event previous 6 month Medical condition require full dose anticoagulation antiplatelet drug Abnormal cardiac function history ischemic heart disease previous 6 month , uncontrolled hypertension , unstable angina , severe cardiac arrhythmia , No brain metastasis , No bone metastasis Previous current malignancy sit No concomitant antitumor treatment include tamoxifen somatostatin analog Unstable systemic disease active uncontrolled infection . Patients ( male female ) use effective contraception reproductive potential .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Hepatocellular carcinoma , advance , bevacizumab , phase II , VGEF , neovascularization</keyword>
</DOC>